Skip to Content

Clinical Trials Detail

A Phase II Trial of Dasatinib in Subjects with Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

Objective
This is a clinical trial of dasatinib that will be administered by mouth, which is investigational.
IRB Protocol Number
12-1625
Principal Investigator(s)
ROBERT DOEBELE

Cancer Trials

  • Lung Cancer
  • All Cancers
Sponsor(s)
Bristol-Myers Squibb
Contact
NIKKI AYODEJI at 720-848-0701
or NIKKI.AYODEJI@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period(s) that can last as long as your cancer is not progressing, and you are not experiencing any unacceptable side effects. A follow up period will consist of phone contact and possible clinic visits. // Eligibility criteria include but are not limited to 18 years or older with cancer and have a certain cell mutation.